Zenas BioPharma, Inc. Common Stock (ZBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.89B
Last updated: Nov 17, 2026 at 4:33 PM ET
Zenas BioPharma, Inc. Common Stock (ZBIO) Statistics
Zenas BioPharma, Inc. Common Stock (ZBIO) has a market cap of $1.89B and an enterprise value of $2.02B. It kept -2580.04% of revenue as net income over the last 12 months. Its share count is up 56.90% from a year earlier.
Total Valuation
Enterprise value is 6.42% above the market cap, as debt exceeds cash.
| Market Cap | $1.89B |
|---|---|
| Enterprise Value | $2.02B |
| Latest price (Nov 17, 2026) | $27.75 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 166.9x and 8.6x.
| P/S Ratio | 166.9x |
|---|---|
| Forward P/S | 85.1x |
| P/B Ratio | 8.6x |
Price Statistics
The stock is down 20.71% over 52 weeks and trades 2.22% below its 50-day average.
| Beta (1Y) | 0.72 |
|---|---|
| 52-Week Change | -20.71% |
| 1-Month Change | +3.89% |
| 3-Month Change | -11.20% |
| 6-Month Change | +55.55% |
| Total Return (1Y) | -20.71% |
| Return vs SPY (1Y) | -34.92% |
| Max Drawdown (1Y) | -64.79% |
| Max Drawdown (3Y) | -74.96% |
| Sharpe Ratio (1Y) | -0.25 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $28.38 |
| 200-Day Average | $25.44 |
| 52-Week Range | $13.50 to $44.60 |
| RSI (14 Days) | 48.7 |
| Average Volume (20 Days) | 497.63K |
Financial Position
Current assets cover 9.42x current liabilities, and total debt is 1.41x shareholder equity.
| Current Ratio | 9.42x |
|---|---|
| Quick Ratio | 9.42x |
| Debt / Equity | 1.41x |
| Interest Coverage | -15.79x |
Returns and Efficiency
Return on invested capital is -104.29% and return on equity is -255.20% over the last 12 months.
| Return on Equity (ROE) | -255.20% |
|---|---|
| Return on Assets (ROA) | -80.24% |
| Return on Invested Capital (ROIC) | -104.29% |
| Return on Capital Employed (ROCE) | -87.31% |
| Asset Turnover | 0.04x |
Scores
ZBIO has an Altman Z-Score of -1.47, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.47 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $21.00M over the last 12 months is up 40.00% from the 12 months before.
| Revenue | $21.00M |
|---|---|
| Revenue Growth (YoY) | +40.00% |
| Gross Profit | $10.99M |
| Operating Income | -$526.40M |
| Pretax Income | -$541.54M |
| Net Income | -$541.81M |
| EBIT | -$533.63M |
| Reported EPS (TTM) | -$6.27 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 31.44% of the $675.22M in total assets.
| Cash and Equivalents | $177.78M |
|---|---|
| Total Debt | $299.36M |
| Net Debt | $121.58M |
| Net Debt Per Share | $1.84 |
| Working Capital | $539.40M |
| Shareholder Equity | $212.31M |
| Book Value Per Share | $3.21 |
| Total Assets | $675.22M |
| Total Liabilities | $462.91M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$242.83M |
|---|---|
| FCF Per Share | -$4.19 |
| Depreciation and Amortization | $3.43M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2506.68%.
| Gross Margin | 52.33% |
|---|---|
| Operating Margin | -2506.68% |
| Pretax Margin | -2578.76% |
| Net Margin | -2580.04% |
| EBIT Margin | -2541.08% |
Dividends and Yields
ZBIO does not pay a dividend.
| Buyback Yield | -19.91% |
|---|---|
| Shareholder Yield | -19.91% |
Peer Position
Against 7 similar companies, ZBIO has the highest P/S.
P/S RatioPeer median 6.8x
ROICPeer median -18.68%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +33.55%
| P/S Ratio | 166.9x vs 6.8x median |
|---|---|
| ROIC | -104.29% vs -18.68% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +40.00% vs +33.55% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ZBIO
What is ZBIO's market cap?
Zenas BioPharma, Inc. Common Stock has a market cap of $1.89B. Its enterprise value, which adds debt and subtracts cash, is $2.02B.
How many shares of ZBIO are outstanding?
Zenas BioPharma, Inc. Common Stock has 66.15M shares outstanding. The count is up 56.90% from a year earlier.
Does ZBIO pay a dividend?
No. Zenas BioPharma, Inc. Common Stock does not pay a dividend.
How much debt does ZBIO have?
Zenas BioPharma, Inc. Common Stock has $299.36M of total debt and $177.78M of cash and equivalents, a net debt position of $121.58M.
ZBIO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors